Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;51(1):52-7.
doi: 10.3349/ymj.2010.51.1.52. Epub 2009 Dec 29.

Delivery of factor VIII gene into skeletal muscle cells using lentiviral vector

Hyun Jeong Jeon  1 , Tae Keun Oh, Oak Hee Kim, Seung Taik Kim
Affiliations

Delivery of factor VIII gene into skeletal muscle cells using lentiviral vector

Hyun Jeong Jeon et al. Yonsei Med J. 2010 Jan.

Abstract

Purpose: This study was designed to investigate whether transduction of lentiviral vectors (LV) carrying human coagulation factor VIII (hFVIII) cDNA into skeletal muscle could increase circulating hFVIII concentrations.

Materials and methods: A LV containing bacterial LacZ gene as a control or human FVIII gene was intramuscularly administered into the thigh muscle of 5 weeks old Sparague-Dawley rats. The plasma human FVIII concentration and neutralizing anti-FVIII antibodies were measured for up to 12 weeks in these experimental animals.

Results: The plasma human FVIII levels in the rats injected with LV carrying FVIII cDNA peaked at post-injection 1st week (5.19 +/- 0.14 ng/mL vs. 0.21 +/- 0.05 ng/mL in control rats , p < 0.05). Elevated hFVIII concentrations were maintained for 4 weeks (2.52 +/- 0.83 ng/mL vs. 0.17 +/- 0.08 ng/mL in control rats, p < 0.05) after a single intramuscular injection. In the Bethesda assay, neutralizing antibodies for FVIII protein were detected only in FVIII-LV injected rats by the 10th week, but not in control rats.

Conclusion: This study suggested that a single administration of an advanced generation LV carrying the human FVIII cDNA resulted in elevation of FVIII level in immune competent rats, and that this gene transfer approach to the skeletal muscle could be an effective tool in treatment of hemophilia A.

Keywords: Gene therapy; hemophilia A; human coagulation factor VIII; lentiviral vector.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

Figures

Fig. 1
Fig. 1
In vitro production of human coagulation factor VIII in HeLa cells transduced with lentiviral vectors (LV). Hela cells (5×105 cells) were transduced with increasing dose of lentiviral vector (ng p24 Gag antigen, which is an index of titer) carrying the human B-domain depleted coagulation factor VIII cDNA. The media were changed 24 hours after initial transduction, and the cells were incubated for an additional 48 hours prior to harvesting the media for the assessment of factor VIII concentration by enzyme-linked immunosorbent assay (ELISA) (n = 2, independent experiments).
Fig. 2
Fig. 2
X-gal staining of tissue harvested from lentiviral vector-injected rats. Four weeks after intramuscular injection of lentivirus containing lacZ gene (1.5×107 infectious units), the following organs were harvested; the lentiviral vector-injected skeletal muscle (A), liver (B), lung (C) and spleen (D). The tissues were sectioned (10 µm) and stained with X-gal to examine the expression of lacZ in vivo, following lentiviral vector transduction. (A) Shows definitive X-gal stained myocytes (×400), (B-D) but no other X-gal-positive cells are detected in the other three organs (×400).
Fig. 3
Fig. 3
Temporal expression of plasma human factor VIII levels following lentiviral vector administration. Plasma factor VIII levels isolated from rats which were injected with lentiviral vector expressing human factor VIII (●, n = 4) or bacterial lacZ (control) rats (□, n = 4) over the course of the experiment. Data are expressed as mean±SD. *p< 0.01.
Fig. 4
Fig. 4
Bethesda assay for anti-human factor VIII antibody. Analysis for antibody against human factor VIII showed that neutralizing antibodies developed in rats injected with pLV-factor VIII after 10 weeks, but not in control rats.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther. 1999;10:2091–2107. - PubMed
    1. Levine P. Clinical manifestations an therapy of hemophilia A and B. In: Colman R, Hirsh J, Marder V, Saizman E, editors. Hemostasis and Thrombosis. 2nd ed. Philadelphia, PA: JB Lippincott; 1987. pp. 97–111.
    1. Furie B, Limentani SA, Rosenfield CG. A practical guide to the evaluation and treatment of hemophilia. Blood. 1994;84:3–9. - PubMed
    1. Saenko EL, Ananyeva NM, Shima N, Hauser CA, Pipe SW. The future of recombinant coagulation factors. J Thromb Haemost. 2003;1:922–930. - PubMed
    1. Kreuz W, Ettingshausen CE, Zyschka A, Oldenburg J, Saguer IM, Ehrenforth S, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28:285–290. - PubMed

Publication types

  NODES
admin 4
INTERN 2
twitter 2